| The multiMiR R package and database: integration of microRNA–target interactions along with their disease and drug associations Y Ru, KJ Kechris, B Tabakoff, P Hoffman, RA Radcliffe, R Bowler, ... Nucleic acids research 42 (17), e133-e133, 2014 | 533 | 2014 |
| Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition J Murai, Y Feng, KY Guoying, Y Ru, SW Tang, Y Shen, Y Pommier Oncotarget 7 (47), 76534, 2016 | 278 | 2016 |
| Comparison of breast cancer molecular features and survival by African and European ancestry in the Cancer Genome Atlas D Huo, H Hu, SK Rhie, ER Gamazon, AD Cherniack, J Liu, TF Yoshimatsu, ... JAMA oncology 3 (12), 1654-1662, 2017 | 252 | 2017 |
| Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer CA Stewart, P Tong, RJ Cardnell, T Sen, L Li, CM Gay, F Masrorpour, ... Oncotarget 8 (17), 28575, 2017 | 196 | 2017 |
| A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment SC Smith, AS Baras, G Dancik, Y Ru, KF Ding, CA Moskaluk, Y Fradet, ... The lancet oncology 12 (2), 137-143, 2011 | 162 | 2011 |
| Translation initiation factor eIF3b expression in human cancer and its role in tumor growth and lung colonization H Wang, Y Ru, M Sanchez-Carbayo, X Wang, JS Kieft, D Theodorescu Clinical cancer research 19 (11), 2850-2860, 2013 | 81 | 2013 |
| Role in tumor growth of a glycogen debranching enzyme lost in glycogen storage disease S Guin, C Pollard, Y Ru, C Ritterson Lew, JE Duex, G Dancik, C Owens, ... Journal of the National Cancer Institute 106 (5), dju062, 2014 | 72 | 2014 |
| Contributions of KRAS and RAL in Non–Small-Cell Lung Cancer Growth and Progression S Guin, Y Ru, M Wynes, R Mishra, X Lu, C Owens, AE Barόn, VT Vasu, ... Journal of Thoracic Oncology 8 (12), 1492-1501, 2013 | 56 | 2013 |
| Biomarkers for prognosis and treatment selection in advanced bladder cancer patients Y Ru, GM Dancik, D Theodorescu Current opinion in urology 21 (5), 420-427, 2011 | 53 | 2011 |
| Common introns within orthologous genes: software and application to plants MD Wilkerson, Y Ru, VP Brendel Briefings in bioinformatics 10 (6), 631-644, 2009 | 37 | 2009 |
| Loss of glycogen debranching enzyme AGL drives bladder tumor growth via induction of hyaluronic acid synthesis S Guin, Y Ru, N Agarwal, CR Lew, C Owens, GP Comi, D Theodorescu Clinical Cancer Research 22 (5), 1274-1283, 2016 | 32 | 2016 |
| CD44 and RHAMM are essential for rapid growth of bladder cancer driven by loss of Glycogen Debranching Enzyme (AGL) D Oldenburg, Y Ru, B Weinhaus, S Cash, D Theodorescu, S Guin BMC cancer 16, 1-12, 2016 | 30 | 2016 |
| A framework to select clinically relevant cancer cell lines for investigation by establishing their molecular similarity with primary human cancers GM Dancik, Y Ru, CR Owens, D Theodorescu Cancer research 71 (24), 7398-7409, 2011 | 30 | 2011 |
| Induction of ER Stress by an AAV5 BDD FVIII Construct Is Dependent on the Strength of the Hepatic-Specific Promoter S Fong, B Handyside, CR Sihn, S Liu, L Zhang, L Xie, R Murphy, ... Molecular Therapy-Methods & Clinical Development 18, 620-630, 2020 | 29 | 2020 |
| Spliceosomal proteins in plants Y Ru, BB Wang, V Brendel Nuclear pre-mRNA Processing in Plants, 1-15, 2008 | 28 | 2008 |
| Neurofilament light is a treatment‐responsive biomarker in CLN2 disease Y Ru, C Corado, RK Soon Jr, AC Melton, A Harris, GK Yu, N Pryer, ... Annals of Clinical and Translational Neurology 6 (12), 2437-2447, 2019 | 25 | 2019 |
| Identifying therapeutic drug targets using bidirectional effect genes K Estrada, S Froelich, A Wuster, CR Bauer, T Sterling, WT Clark, Y Ru, ... Nature Communications 12 (1), 2224, 2021 | 20* | 2021 |
| SplicingTypesAnno: Annotating and quantifying alternative splicing events for RNA-Seq data X Sun, F Zuo, Y Ru, J Guo, X Yan, G Sablok Computer methods and programs in biomedicine 119 (1), 53-62, 2015 | 13 | 2015 |
| Evidence of intratumoral localization, activation, and immunomodulatory effect of CX-072, a PROBODY therapeutic targeting PD-L1, in a phase I/II trial [poster] SK Lyman, A Naing, IA Zein, Y Ru, B Howng, MB Winter, O Vasiljeva, ... American Society of Clinical Oncology Virtual Meeting, 29-31, 2020 | 9 | 2020 |
| Comparative Survival Analysis of Invasive Breast Cancer Patients Treated by a US Military Medical Center and Matched Patients From the US General Population Y Ru, J Liu, JL Fantacone-Campbell, K Zhu, AJ Kovatich, JA Hooke, ... Military Medicine 182 (11-12), e1851-e1858, 2017 | 8 | 2017 |
Dan Theodorescu MD, PhDCedars Sinai Medical Center在 cshs.org 的电子邮件经过验证
